Hi everyone, and welcome to today's conference. This is Mattias Perjos, the CEO of Getinge. And with me today I have our CFO, Agneta Palmér. So in today's conference, we will go through our performance and some of the highlights from the second quarter before we open up for a Q&A.
So we can move over to page number two, please.
And as usual, let's start by looking at the development of our strategic KPIs. We continue to clearly track in line with plan to increase the share of sales from recurring revenue, accelerating the share of sales from high-margin products like, for example, our offering of consumables in infection control and beta bags in sterile transfer. This is all supported by solid and effective quality processes, and sales from recurring revenue continue to make up about two-thirds, and high-margin products are now at 70%. For quality, the number of field actions in relation to sales has decreased significantly, and we're pacing a lot better than last year. These improvements should, of course, be achieved through responsible leverage and also an attractive long-term return on invested capital.
With that, we can move over to page number three, please.
So if we zoom in on the second quarter and some of the financial key takeaways for the quarter overall, we delivered a healthy financial performance with solid top-line growth. Net sales grew 4.6% organically, with positive development in most of the business areas. Order intake increased by 6.2% organically. Adjusted gross and EBITDA margins were up in the quarter as a result of the IEEPA tariff refund, and also continued positive underlying performance in our business. This led to a strong cash flow and a strong financial position with financial leverage at 1.7 times, so well below the 2.5 times adjusted EBITDA as we have as our internal threshold; we can then move over to page number four and some of the key events in the quarter. So we take a step back here and look at some of the key events in our business across the second quarter. When it comes to the offering and customers, we continue to be innovative. In the quarter, we launched three products which will benefit customers and patients. We have launched the Aquadis Endo 110, which is the next generation of automated endoscope reprocessing, while the Fluobeam LS expands the fluorescence imaging portfolio for small incision surgery. We also launched the Vasoview Hemopro 3, which is the latest evolution of our EVT platform supporting coronary artery bypass grafting procedures. In Hamburg, Germany, we opened a digital innovation center with the purpose of accelerating the path to a more intelligent perioperative workflow. Furthermore, in Surgical Workflows, we strengthened our infection prevention offering in endoscopy by acquiring Pennamed, a UK-based distributor of endoscopic consumables. We, of course, also monitor the situation in the Middle East closely. Our first priority remains to tend to our employees in the region and continue to support our customers. The region makes up about 2% of sales, whereas Saudi Arabia is around half. And thanks to our team's diligent efforts to reroute shipments, to implement sourcing initiatives and also take other mitigating actions, the impact on both top line and costs has been very limited so far. Naturally, this might become more of a headwind if the situation worsens, and we continue to follow this very closely. If we then move to sustainability and quality, we reached an important regulatory milestone in June when we submitted the 510(k) application to the FDA for our Cardiosave intra-aortic balloon pump. I'm also happy to see that several of our sustainability KPIs are trending in the right direction. For example, when you look at the product quality KPIs and the greenhouse gas emissions noted here on the slide, as briefly mentioned. Also we. When it comes to our tariffs that we communicated separately, we did receive an IEEPA tariff refund in the quarter of approximately $36 million. We can then move over to page number five and we will discuss our top line performance. So when it comes to top lines, we start with order intake. The organic order intake in Acute Care Therapies increased primarily in ECLS therapy consumables, in our covered stents portfolio, and within Vasoview Hemopro 3. When it comes to Life Science, the organic order intake rose sharply during the quarter following double-digit growth in sterile transfer and in bioprocessing, while continuing to decline in other areas as a result of geopolitical uncertainty, the impact that this has on decision-making, and the continued challenging investment climate for pharma. The organic order intake for Surgical Workflows increased slightly, driven by a strong performance in infection control, while digital health solutions and Surgical Workflows services noted a decline in the quarter. Then, when it comes to net sales, we had 4.6% organic growth. Acute Care Therapies increased its net sales organically, primarily due to sales of stents, ECLS therapy consumables, as well as intra-aortic balloon pumps and consumables in the cardiac assist subsegment. In Life Science, organic net sales fell slightly despite robust growth in all product categories except for WIS and in Surgical Workflows. Organic net sales increased following growth in surgical workflows as well as service and consumables in infection control. So with that, we can move over to page number six, please. And I hand over to you, Agneta.